Sarah Cannon
October 31, 2019
Daiichi Sankyo Initiates Clinical Trial with its 4th DXd Antibody Drug ...

The first patient has been dosed in a first-in-human phase 1/2 study evaluating DS-7300, an investigational B7-H3 targeting antibody drug conjugate...

Read More
Sarah Cannon
May 30, 2019
Sarah Cannon to Present Latest Cancer Research Insights at 2019 American...

NASHVILLE, TENN., May 30, 2019 – Today, Sarah Cannon announced that it will present its latest cancer research insights through more than 100...

Read More